Patent intelligence · US
US 9670268
Pharmaceutical composition and method of preparing same
Pharmaceutical composition and method of preparing same
Patent details — US 9670268
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 6, 2017
- Expiration
- Jun 1, 2037
- Applicant
- SAISEI MIRAI CLINIC
- Claims
- 2
- CPC classes
- A61K, A61K35/16, A61K38/47, A61P
Quick answer
US 9670268 (Pharmaceutical composition and method of preparing same) is held by SAISEI MIRAI CLINIC. Status: granted. Granted Jun 6, 2017. Expires Jun 1, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SAISEI MIRAI CLINIC
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K35/16, A61K38/47, A61P, A61P31/00, A61P35/00
More from SAISEI MIRAI CLINIC
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9670268?
US 9670268 (Pharmaceutical composition and method of preparing same) is held by SAISEI MIRAI CLINIC. Status: granted. Granted Jun 6, 2017. Expires Jun 1, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9670268?
SAISEI MIRAI CLINIC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9670268 expire?
Our index shows an expiration date of Jun 1, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.